Amicus Therapeutics, Inc. (NASDAQ:FOLD) Director Donald J. Hayden, Jr. sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $15.00, for a total transaction of $300,000.00. Following the sale, the director now owns 25,814 shares in the company, valued at approximately $387,210. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Amicus Therapeutics, Inc. (FOLD) traded up $0.36 during trading on Thursday, hitting $15.87. 2,770,000 shares of the stock were exchanged, compared to its average volume of 2,180,000. The company has a market capitalization of $2,640.00, a PE ratio of -8.67 and a beta of 1.72. Amicus Therapeutics, Inc. has a 52 week low of $5.07 and a 52 week high of $16.60. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $10.90 million for the quarter, compared to analyst estimates of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The firm’s revenue was up 419.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.33) EPS. equities analysts anticipate that Amicus Therapeutics, Inc. will post -1.56 EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of FOLD. Strs Ohio acquired a new position in shares of Amicus Therapeutics in the third quarter valued at approximately $102,000. Tudor Investment Corp ET AL acquired a new position in shares of Amicus Therapeutics in the second quarter valued at approximately $124,000. Aperio Group LLC increased its stake in shares of Amicus Therapeutics by 13.5% in the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 1,663 shares during the period. Zacks Investment Management acquired a new position in shares of Amicus Therapeutics in the second quarter valued at approximately $145,000. Finally, Birchview Capital LP acquired a new position in shares of Amicus Therapeutics in the third quarter valued at approximately $151,000.
FOLD has been the subject of a number of recent research reports. JPMorgan Chase & Co. restated an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Chardan Capital reissued a “buy” rating and set a $16.50 price objective (down previously from $17.50) on shares of Amicus Therapeutics in a report on Wednesday, September 13th. Zacks Investment Research raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Tuesday, October 10th. Cowen reissued an “outperform” rating and set a $18.00 price objective (up previously from $16.00) on shares of Amicus Therapeutics in a research note on Thursday, September 14th. Finally, BidaskClub lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $18.31.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/11/amicus-therapeutics-inc-fold-director-sells-300000-00-in-stock.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.